Deals this week: Hugel, Guangdong Zhongsheng Pharmaceutical, Valeant Pharmaceuticals International


South Korean pharmaceutical company Hugel has announced the private placement of 985,217 common stock shares priced at KRW360,001.9 ($316.2) a share to raise KRW354.68bn ($311.52m) in gross proceeds.

Chinese pharmaceutical company Guangdong Zhongsheng Pharmaceutical has announced a public offering of medium-term notes due 2022 to raise up to CNY1.3bn ($191.64m) in proceeds.

Valeant Pharmaceuticals International has announced plans to divest its speciality drug business, Obagi Medical Products, to China-based fund Haitong International Zhonghua Finance Acquisition, for $190m.

"Chinese pharmaceutical company Guangdong Zhongsheng Pharmaceutical has announced a public offering of medium-term notes due 2022 to raise up to CNY1.3bn ($191.64m) in proceeds."

The Canadian speciality pharmaceutical company will use the proceeds from the divesture to repay its term loan.

Thermo Fisher Scientific has announced three public offerings of floating rate senior notes and senior notes to raise €2.6bn ($2.98bn) in total.

The floating rate senior notes are due July 2019, while the senior notes are due 23 January 2026, 24 July 2029 and 24 July 2037, and carry a rate of 1.4%, 1.95% and 2.875% respectively.

Thermo Fisher is an equipment, analytical instruments and reagents provider based in the US.